This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Hypertension

Apelin (APLN); microRNA-424 (miR-424);
miR-503

In vitro and rodent studies suggest miR-424 and miR-503 could help treat pulmonary arterial hypertension (PAH). In human pulmonary artery endothelial cells, decreased expression of miR-424 and miR-503 was associated with increased proliferation of pulmonary artery endothelial and smooth muscle cells, which contributes to PAH. In two rat models of PAH, lentiviral-mediated lung delivery of miR-424 and the rat homolog of miR-503 decreased pulmonary hypertension compared with a control vector. Next steps include developing a nonviral method for microRNA delivery to the lungs.

SciBX 6(3); doi:10.1038/scibx.2013.55
Published online Jan. 24, 2013

Patent application filed; available for licensing

Kim, J. et al. Nat. Med.; published online Dec. 23, 2012;
doi:10.1038/nm.3040
Contact: Hyung Chun, Yale School of Medicine,
New Haven, Conn.
e-mail:

hyung.chun@yale.edu